Filter Results
:
(127)
Show Results For
-
All HBS Web
(127)
- News (44)
- Research (61)
- Multimedia (1)
- Faculty Publications (35)
Show Results For
-
All HBS Web
(127)
- News (44)
- Research (61)
- Multimedia (1)
- Faculty Publications (35)
- January 2014 (Revised June 2014)
- Case
23andMe: Genetic Testing for Consumers (A)
By: John A. Quelch and Margaret L. Rodriguez
On November 22, 2013, the direct-to-consumer genetic testing provider, 23andMe, received a letter from the U.S. Food and Drug Administration (FDA) ordering the company to halt the sale and promotion of its genetic testing kit. The FDA stated that the product was...
View Details
Keywords:
Public Health;
Genome Testing;
Health Care;
Ancestry;
23andMe;
Marketing;
Product Launch;
Health;
Health Care and Treatment;
Health Testing and Trials;
Genetics;
Strategy;
Health Industry;
United States
Quelch, John A., and Margaret L. Rodriguez. "23andMe: Genetic Testing for Consumers (A)." Harvard Business School Case 514-086, January 2014. (Revised June 2014.)
- July 2013
- Case
Novozymes: Establishing the Cellulosic Ethanol Value Chain
By: Willy Shih and Sen Chai
As the world's largest producer of industrial enzymes, Novozymes had invested heavily for many years to bio-engineer enzymes that could break down cellulose into fermentable sugar. In 2010, the company had launched what it thought would become a breakthrough product... View Details
Keywords:
System Complexity;
Industrial Enzymes;
Ethanol;
Collulosic Ethanol;
Fermentation;
Genomics;
Genetic Engineering;
Value Chain;
Assembling Value Chain;
Energy Sources;
Renewable Energy;
Collaborative Innovation and Invention;
Innovation and Management;
Innovation Strategy;
Technological Innovation;
Management;
Growth and Development Strategy;
Industry Growth;
Production;
Research;
Research and Development;
Science;
Genetics;
Natural Environment;
Environmental Sustainability;
Science-Based Business;
Business Strategy;
Commercialization;
Vertical Integration;
Agriculture and Agribusiness Industry;
Biotechnology Industry;
Energy Industry;
Denmark;
United States
Shih, Willy, and Sen Chai. "Novozymes: Establishing the Cellulosic Ethanol Value Chain." Harvard Business School Case 614-001, July 2013.
- 09 Mar 2018
- News
Master Protocols in Oncology: A Review of the Landscape
- June 1997 (Revised March 2001)
- Case
Genset Initial Public Offering (A)
By: Paul A. Gompers and Jeffrey M. Anapolsky
Pascal Brandys, founder and CEO of Genset, must decide whether to take this young biotechnology company public. If so, should he do a dual offering in both France and the U.S.? The case also explores the business models in genomics research.
View Details
Keywords:
Business Model;
Initial Public Offering;
Genetics;
Going Public;
Management Teams;
Biotechnology Industry;
France;
United States
Gompers, Paul A., and Jeffrey M. Anapolsky. "Genset Initial Public Offering (A)." Harvard Business School Case 297-096, June 1997. (Revised March 2001.)
- Article
One Obstacle to Curing Cancer: Patient Data Isn't Shared
By: Richard G. Hamermesh and Kathy Giusti
Precision Medicine requires large datasets to identify the mutations that lead to various cancers. Currently, genomic information is hoarded in fragmented silos within numerous academic medical centers, pharmaceutical companies, and some disease-based foundations. For...
View Details
Keywords:
Healthcare;
Technological And Scientific Innovation;
Cancer Care In The U.S.;
Cancer Treatment;
Precision Medicine;
Personalized Medicine;
Data Sharing;
Technological Innovation;
Analytics and Data Science;
Health Disorders;
Medical Specialties;
Research and Development;
Customization and Personalization;
Health Industry;
United States
Hamermesh, Richard G., and Kathy Giusti. "One Obstacle to Curing Cancer: Patient Data Isn't Shared." Harvard Business Review (website) (November 28, 2016).
- 21 Jun 2018
- Video
KPMA HBX Live Cracking the Data Aggregation Problem - Richard Hamermesh
- 21 Jun 2017
- News
A New Approach to Safely Sharing Cancer Patients’ Data
- Article
Beyond Magic Bullets: True Innovation in Health Care
By: Vaibhav A. Narayan, Marco Mohwinckel, Gary Pisano, Michael Yang and Husseini Manji
The molecular medicine revolution—based on advances in fields such as genomics and network modeling in the decade since the human genome sequence was completed—has changed the way we think about, study, and approach the development of novel therapies. However, these...
View Details
Keywords:
Integration;
Business Model;
Organizational Structure;
Health Care and Treatment;
Innovation and Invention;
Pharmaceutical Industry
Narayan, Vaibhav A., Marco Mohwinckel, Gary Pisano, Michael Yang, and Husseini Manji. "Beyond Magic Bullets: True Innovation in Health Care." Nature Reviews: Drug Discovery 12, no. 2 (February 2013): 85–86.
- April 2002
- Case
In vivo to in vitro to in silico: Coping with Tidal Waves of Data at Biogen
By: Juan Enriquez-Cabot, Gary P. Pisano and Gaye Bok
Biogen is a successful biotech company facing a critical juncture. CEO John Mullen ponders how technological changes introduced into the research function will shape larger corporate decisions. This world in which biotechnology companies operated had changed...
View Details
Keywords:
Change;
Decisions;
Product Development;
Research and Development;
Expansion;
Technology;
Biotechnology Industry
Enriquez-Cabot, Juan, Gary P. Pisano, and Gaye Bok. "In vivo to in vitro to in silico: Coping with Tidal Waves of Data at Biogen." Harvard Business School Case 602-122, April 2002.
Mitchell Tang
Mitchell Tang graduated in 2016 from the University of Pennsylvania, where he completed dual-degrees in computational biology and economics as part of the Vagelos Program in Life Sciences and Management (LSM). While at Penn, Mitchell was involved in research at the... View Details
- 2003
- Case
Corning Microarray Technologies
By: Vijay Govindarajan, Chris Trimble and Gautam Bellur
In mid-2000, the scientific community reached a momentous milestone—the complete mapping of the human genome. Researchers in the field of genomics were anxious to dig into a tremendous array of newly possible scientific inquiries, and needed efficient experimental...
View Details
- December 2000
- Case
Friona Industries, L.P.
By: Ray A. Goldberg, Carin-Isabel Knoop and Cate Reavis
As the food industry becomes more sophisticated, and as genomics and other factors provide for quality control from the producers to the consumers in the food chain, the beef industry has been one of the last commodity systems to organize the vertical systems to...
View Details
Keywords:
Customer Satisfaction;
Customer Value and Value Chain;
Food;
Management Systems;
Supply and Industry;
Performance Consistency;
Quality;
Partners and Partnerships;
Food and Beverage Industry;
Retail Industry
Goldberg, Ray A., Carin-Isabel Knoop, and Cate Reavis. "Friona Industries, L.P." Harvard Business School Case 901-009, December 2000.
- 2023
- Working Paper
PRIMO: Private Regression in Multiple Outcomes
By: Seth Neel
We introduce a new differentially private regression setting we call Private Regression in Multiple Outcomes (PRIMO), inspired the common situation where a data analyst wants to perform a set of l regressions while preserving privacy, where the covariates...
View Details
Neel, Seth. "PRIMO: Private Regression in Multiple Outcomes." Working Paper, March 2023.
- September 2017 (Revised February 2023)
- Case
Intermountain Healthcare: Pursuing Precision Medicine
By: Richard G. Hamermesh, Kathy E. Giusti, Robert S. Huckman and Julia Kelley
Headquartered in Salt Lake City, Intermountain Healthcare operates 23 hospitals and hundreds of clinics in Utah and Idaho and provides insurance to approximately 850,000 patients through its insurance arm, SelectHealth. In 2013, Intermountain, known for its commitment...
View Details
Keywords:
Precision Medicine;
Healthcare;
Innovation;
Cancer;
Cancer Research;
Health Care;
Technology;
Health Care and Treatment;
Innovation Leadership;
Disruptive Innovation;
Entrepreneurship;
Decision Choices and Conditions;
Health Industry;
Insurance Industry;
Utah;
United States;
North America
Hamermesh, Richard G., Kathy E. Giusti, Robert S. Huckman, and Julia Kelley. "Intermountain Healthcare: Pursuing Precision Medicine." Harvard Business School Case 818-018, September 2017. (Revised February 2023.)
- 30 Mar 2020
- News
Why Is the U.S. Behind on Coronavirus Testing?
- October 2011
- Case
Gene Sequencing: Staking a Position in an Expanding Industry
By: Richard G. Hamermesh, Mara Aspinall and Phillip Andrews
Towards the end of 2010, companies in the gene sequencing industry were pushing aggressive R&D programs to develop technologies and products in the race to sequence the entire human genome at a cost of $1,000. It remained to be seen when the "$1,000 genome" would...
View Details
Keywords:
Genetics;
Business Growth and Maturation;
Business Plan;
Competition;
Venture Capital;
Biotechnology Industry
Hamermesh, Richard G., Mara Aspinall, and Phillip Andrews. "Gene Sequencing: Staking a Position in an Expanding Industry." Harvard Business School Case 812-004, October 2011.
- 09 Mar 2009
- News
2009, Not 1992
- January 2002 (Revised October 2005)
- Case
General Electric Medical Systems 2002
By: Tarun Khanna and James Weber
Discusses one of General Electric's flagship divisions--the world's leading provider of medical diagnostic imaging equipment. Provides an opportunity to examine a multinational confronting massive technological and demographic changes around the world. Genomics has...
View Details
Keywords:
Information Technology;
Business Model;
Change Management;
Multinational Firms and Management;
Genetics;
Customer Value and Value Chain;
Age;
Medical Devices and Supplies Industry;
China;
United States
Khanna, Tarun, and James Weber. "General Electric Medical Systems 2002." Harvard Business School Case 702-428, January 2002. (Revised October 2005.)
- August 2009 (Revised January 2012)
- Case
Pandora: Royalties Kill the Web Radio Star? (A)
By: Robert C. Pozen and Alex Curtis Rosenfeld
Joe Kennedy, president and CEO of Pandora, one of the largest and most popular web (Internet) radio broadcasters, had just received bad news. The Copyright Royalty Board (CRB) had announced its decision to increase the royalties required to be paid by the web radio...
View Details
Keywords:
Profit;
Governing Rules, Regulations, and Reforms;
Copyright;
Laws and Statutes;
Rights;
Internet and the Web;
Media and Broadcasting Industry
Pozen, Robert C., and Alex Curtis Rosenfeld. "Pandora: Royalties Kill the Web Radio Star? (A)." Harvard Business School Case 310-026, August 2009. (Revised January 2012.)